{"id":1800,"date":"2015-08-01T15:10:17","date_gmt":"2015-08-01T19:10:17","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=1800"},"modified":"2015-12-24T16:57:07","modified_gmt":"2015-12-24T21:57:07","slug":"qidp-drugs-4th-edition","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2015\/08\/01\/1800\/qidp-drugs-4th-edition\/","title":{"rendered":"QIDP Drugs – 4th Edition"},"content":{"rendered":"
\"QIDP<\/a>
Status 8\/3\/2015<\/figcaption><\/figure>\n

>>> For the latest QIDP list, please click HERE<\/a> \u00a0<<<<\/span><\/p>\n

Since our\u00a0last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table\u00a0which includes compound, sponsor\u00a0and development stage (Phase). It also indicates whether a drug has been\u00a0the topic of a more detailed write-up here in\u00a0our blog pages. As before, the table is searchable.<\/p>\n

This is a snapshot of a dynamic situation. If I made a\u00a0mistake or omitted a drug which should have been included, please leave me a comment.<\/p>\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Company<\/th>Drug Name<\/th>Antibiotic Class<\/th>Phase<\/th>Action Site<\/th>Antimicrobial_Class<\/th>Blog<\/th>\n<\/tr>\n<\/thead>\n
Cardeas Pharma<\/td>Amikacin + fosfomycin<\/td>aminoglycoside<\/td>Phase 2<\/td>pulmonary<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Insmed Pharmaceuticals<\/td>Arikace<\/td>aminoglycoside<\/td>Phase 3<\/td>pulmonary<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Bayer<\/td>Amikacin Inhale<\/td>aminoglycoside<\/td>Phase 3<\/td>pulmonary<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Meiji Seika Pharma<\/td>ME-1100<\/td>aminoglycoside<\/td>Phase 1<\/td>topical<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Achaogen<\/td>Plazomicin<\/td>aminoglycoside<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Astellas \/ Basilea<\/td>Isavuconazole<\/td>azole<\/td>Approved US<\/td>systemic<\/td>antifungal<\/td>1<\/td>\n<\/tr>\n
Symbiomix<\/td>SYM-1219<\/td>azole<\/td>Phase 3<\/td>systemic<\/td>antifungal<\/td><\/td>\n<\/tr>\n
Microbion Corporation<\/td>BisEDT Antimicrobial Gel<\/td>bismuth-thiol<\/td>Phase 1<\/td>topical<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
The Medicines Company<\/td>Meropenem + RPX7009<\/td>B-lactam \/ BLI<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Merck<\/td>Imipenem\/cilastatin + MK-7655<\/td>B-lactam \/ BLI<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Merck \/ Cubist<\/td>Ceftolozane + tazobactam<\/td>B-lactam \/ BLI<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Actavis<\/td>Ceftazidime + avibactam<\/td>B-lactam \/ BLI<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
RedHill Biopharma<\/td>RHB-105<\/td>combination<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Cellceutix Pharmaceuticals<\/td>Brilacidin<\/td>defensin-mimetic<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Motif<\/td>Iclaprim<\/td>DHFR inhibitor<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Debiopharm Pharmaceuticals<\/td>Deb-1450<\/td>Fab-l inhibitor<\/td>Phase 1<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Cempra Pharmaceuticals<\/td>Fusidic Acid<\/td>fusidic acid<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Scynexis Pharmaceuticals<\/td>SCY-078<\/td>glucan synthase inhibitor<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Cidara Therapeutics<\/td>CD-101<\/td>glucan synthase inhibitor<\/td>Pre-Clin<\/td>systemic<\/td>antifungal<\/td><\/td>\n<\/tr>\n
The Medicines Company<\/td>Oritavancin<\/td>glycopeptide<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Durata Therapeutics<\/td>Dalbavancin<\/td>glycopeptide<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Merck \/ Cubist<\/td>Surotomycin<\/td>glycopeptide<\/td>Phase 3<\/td>GI only<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Cempra Pharmaceuticals<\/td>Solithromycin<\/td>macrolide \/ ketolide<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Wockhardt<\/td>WCK-4873<\/td>macrolide \/ ketolide<\/td>Phase 1<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Valley Fever Solutions<\/td>NikZ<\/td>nikkomycin<\/td>Phase 1<\/td>systemic<\/td>antifungal<\/td>1<\/td>\n<\/tr>\n
Roche \/ Polyphor<\/td>POL-7080<\/td>other<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Summit plc<\/td>SMT-19969<\/td>other<\/td>Phase 2<\/td>GI only<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Merck \/ Cubist \/ Trius<\/td>Tedizolid<\/td>oxazolidinone<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Melinta Therapeutics<\/td>Radezolid<\/td>oxazolidinone<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Actelion Pharmaceuticals<\/td>Cadazolid<\/td>oxazolidinone<\/td>Phase 3<\/td>GI only<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Nabriva Therapeutics<\/td>BC-3781<\/td>pleuromutilin<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Melinta Therapeutics<\/td>Delafloxacin<\/td>quinolone<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
Actavis\/Furiex<\/td>Avarofloxacin<\/td>quinolone<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Bayer<\/td>Ciprofloxacin DPI<\/td>quinolone<\/td>Phase 3<\/td>pulmonary<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Wockhardt Pharmaceuticals<\/td>WCK-2349<\/td>quinolone<\/td>Phase 1<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Aradigm Pharmaceuticals<\/td>Ciprofloxacin<\/td>quinolone<\/td>Phase 3<\/td>pulmonary<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
MerLion Pharmaceuticals<\/td>Finafloxacin<\/td>quinolone<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Wockhardt Pharmaceuticals<\/td>WCK-771<\/td>quinolone<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
TaiGen Biotechnology<\/td>Nemonoxacin<\/td>quinolone<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
AstraZeneca \/ Entasis<\/td>AZD-0914<\/td>quinolone<\/td>Phase 2<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Paratek Pharmaceuticals<\/td>Omadacycline<\/td>tetracycline<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n
The Medicines Company<\/td>Minocycline<\/td>tetracycline<\/td>Approved US<\/td>systemic<\/td>antibacterial<\/td><\/td>\n<\/tr>\n
Tetraphase Pharmaceuticals<\/td>Eravacycline<\/td>tetracycline<\/td>Phase 3<\/td>systemic<\/td>antibacterial<\/td>1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n

Here some summary statistics which may be of interest:<\/p>\n